Kenneth Carl Anderson
Known title: DirectorCIK: 0001824862
Associated companies
Transaction History
| CCCC | ▲ Buy | Grant | 3,662 | $11K | 10/1/2026 | View on chart |
| CCCC | ▲ Buy | Grant | 2,650 | $12K | 7/1/2026 | View on chart |
| CCCC | ▲ Buy | Option Exercise | 1,070 | $2K | 6/1/2026 | View on chart |
| CCCC | ▲ Buy | Grant | 4,259 | $11K | 4/1/2026 | View on chart |
| CCCC | ▲ Buy | Grant | 5,958 | $11K | 1/2/2026 | View on chart |
| CCCC | ▲ Buy | Grant | 5,349 | $12K | 10/1/2025 | View on chart |
| CCCC | ▲ Buy | Grant | 7,616 | $12K | 7/1/2025 | View on chart |
| CCCC | ▲ Buy | Grant | 7,841 | $11K | 4/1/2025 | View on chart |
| CCCC | ▲ Buy | Grant | 3,074 | $11K | 1/2/2025 | View on chart |
| CCCC | ▲ Buy | Grant | 2,023 | $11K | 10/1/2024 | View on chart |
| CCCC | ▲ Buy | Grant | 2,320 | $11K | 7/1/2024 | View on chart |
| CCCC | ▲ Buy | Grant | 1,389 | $11K | 4/1/2024 | View on chart |
| CCCC | ▲ Buy | Grant | 1,725 | $11K | 1/2/2024 | View on chart |
| CCCC | ▲ Buy | Grant | 6,617 | $11K | 10/2/2023 | View on chart |
| CCCC | ▲ Buy | Grant | 3,976 | $11K | 7/3/2023 | View on chart |
| CCCC | ▲ Buy | Grant | 3,516 | $11K | 4/3/2023 | View on chart |
| CCCC | ▲ Buy | Option Exercise | 444 | $2K | 1/6/2023 | View on chart |
| CCCC | ▲ Buy | Option Exercise | 268 | $565 | 1/6/2023 | View on chart |
| CCCC | ▲ Buy | Grant | 1,568 | $10K | 1/3/2023 | View on chart |
| CCCC | ▲ Buy | Option Exercise | 267 | $563 | 10/3/2022 | View on chart |
| CCCC | ▲ Buy | Option Exercise | 445 | $2K | 10/3/2022 | View on chart |
| CCCC | ▲ Buy | Grant | 1,150 | $10K | 10/3/2022 | View on chart |
| CCCC | ▲ Buy | Option Exercise | 535 | $1K | 7/15/2022 | View on chart |
| CCCC | ▲ Buy | Option Exercise | 889 | $4K | 7/15/2022 | View on chart |
| CCCC | ▲ Buy | Grant | 1,246 | $10K | 7/1/2022 | View on chart |
| CCCC | ▲ Buy | Grant | 341 | $9K | 4/4/2022 | View on chart |
| CCCC | ▲ Buy | Option Exercise | 803 | $2K | 1/26/2022 | View on chart |
| CCCC | ▲ Buy | Option Exercise | 1,334 | $7K | 1/26/2022 | View on chart |
| CCCC | ▲ Buy | Grant | 278 | $9K | 1/4/2022 | View on chart |
| CCCC | ▲ Buy | Grant | 194 | $9K | 10/4/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
C4 Therapeutics Shares New Biomarker Data from Phase 1 Trials
C4 Therapeutics presented new biomarker results from its cemsidomide phase 1 trial with dexamethasone and a phase 1b trial with elranatamab at the 23rd International Myeloma Society meeting. The data provide early insights into how the drugs may work in relapsed/refractory multiple myeloma patients. This update highlights the company’s ongoing clinical development efforts.
C4 Therapeutics Shares New Biomarker Data from Phase 1 Trials. C4 Therapeutics presented new biomarker results from its cemsidomide phase 1 trial with dexamethasone and a phase 1b trial with elranatamab at the 23rd International Myeloma Society meeting. The data provide early insights into how the drugs may work in relapsed/refractory multiple myeloma patients. This update highlights the company’s ongoing clinical development efforts.